Ameliorative effect of cerium oxide nanoparticles against Freund's complete adjuvant-induced arthritis
Aim: To assess the mechanistic effects of cerium oxide nanoparticles (CONPs) on Freund's complete adjuvant (FCA)-induced rheumatoid arthritis in rats. Methods: CONPs were characterized and evaluated in vitro (RAW 264.7 macrophages) and in vivo (FCA-induced rheumatoid arthritis model). Results:In vitro treatment with CONPs significantly reduced lipopolysaccharide-induced oxidative stress (as evident from dichlorodihydrofluorescein diacetate staining), diminished mitochondrial stress (as observed with tetraethylbenzimidazolylcarbocyanine iodide staining) and reduced superoxide radicals. In vivo, CONPs exhibited anti-rheumatoid arthritis activity, as evident from results of paw volume, x-ray, clinical scoring, levels of cytokines (IL-17, IL-1β, TNF-α and TGF-β1) and histology. Conclusion: We provide preclinical proof that CONPs may be a novel futuristic nanoparticle-based approach for therapy of rheumatoid arthritis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Nanomedicine (London, England) - 17(2022), 6 vom: 16. März, Seite 383-404 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Allawadhi, Prince [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.03.2022 Date Revised 31.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/nnm-2021-0172 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336575017 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336575017 | ||
| 003 | DE-627 | ||
| 005 | 20231225232442.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/nnm-2021-0172 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1121.xml |
| 035 | |a (DE-627)NLM336575017 | ||
| 035 | |a (NLM)35124975 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Allawadhi, Prince |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ameliorative effect of cerium oxide nanoparticles against Freund's complete adjuvant-induced arthritis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.03.2022 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: To assess the mechanistic effects of cerium oxide nanoparticles (CONPs) on Freund's complete adjuvant (FCA)-induced rheumatoid arthritis in rats. Methods: CONPs were characterized and evaluated in vitro (RAW 264.7 macrophages) and in vivo (FCA-induced rheumatoid arthritis model). Results:In vitro treatment with CONPs significantly reduced lipopolysaccharide-induced oxidative stress (as evident from dichlorodihydrofluorescein diacetate staining), diminished mitochondrial stress (as observed with tetraethylbenzimidazolylcarbocyanine iodide staining) and reduced superoxide radicals. In vivo, CONPs exhibited anti-rheumatoid arthritis activity, as evident from results of paw volume, x-ray, clinical scoring, levels of cytokines (IL-17, IL-1β, TNF-α and TGF-β1) and histology. Conclusion: We provide preclinical proof that CONPs may be a novel futuristic nanoparticle-based approach for therapy of rheumatoid arthritis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a DCFDA | |
| 650 | 4 | |a MTT | |
| 650 | 4 | |a RAW macrophages | |
| 650 | 4 | |a cerium oxide nanoparticles | |
| 650 | 4 | |a freund’s complete adjuvant | |
| 650 | 4 | |a immunology | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a nanoceria | |
| 650 | 4 | |a rheumatoid arthritis | |
| 650 | 4 | |a x-rays | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Cerium |2 NLM | |
| 650 | 7 | |a 30K4522N6T |2 NLM | |
| 650 | 7 | |a ceric oxide |2 NLM | |
| 650 | 7 | |a 619G5K328Y |2 NLM | |
| 650 | 7 | |a Freund's Adjuvant |2 NLM | |
| 650 | 7 | |a 9007-81-2 |2 NLM | |
| 700 | 1 | |a Khurana, Amit |e verfasserin |4 aut | |
| 700 | 1 | |a Sayed, Nilofer |e verfasserin |4 aut | |
| 700 | 1 | |a Godugu, Chandraiah |e verfasserin |4 aut | |
| 700 | 1 | |a Vohora, Divya |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine (London, England) |d 2006 |g 17(2022), 6 vom: 16. März, Seite 383-404 |w (DE-627)NLM17228452X |x 1748-6963 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2022 |g number:6 |g day:16 |g month:03 |g pages:383-404 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/nnm-2021-0172 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2022 |e 6 |b 16 |c 03 |h 383-404 | ||